Current studentsExisting staffContact us
 

Perhexiline and hypertrophic cardiomyopathy: A new horizon for metabolic modulation

Simple item page
dc.contributor.authorHorowitz, J.
dc.contributor.authorChirkov, Y.
dc.date.issued2010
dc.description.statementofresponsibilityJohn D. Horowitz and Yuliy Y. Chirkov
dc.identifier.citationCirculation, 2010; 122(16):1547-1549
dc.identifier.doi10.1161/CIRCULATIONAHA.110.981464
dc.identifier.issn0009-7322
dc.identifier.issn1524-4539
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]
dc.identifier.urihttp://hdl.handle.net/2440/62776
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.rights© 2010 American Heart Association, Inc.
dc.source.urihttps://doi.org/10.1161/circulationaha.110.981464
dc.subjectMyocardium
dc.subjectHumans
dc.subjectCardiomyopathy, Hypertrophic
dc.subjectPerhexiline
dc.subjectCarnitine O-Palmitoyltransferase
dc.subjectCardiovascular Agents
dc.subjectEnergy Metabolism
dc.subjectExercise Tolerance
dc.titlePerhexiline and hypertrophic cardiomyopathy: A new horizon for metabolic modulation
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications